Can the Time Window for Administration of Thrombolytics in Stroke be Increased?

CNS Drugs

Volumn 17, Issue 14, 2003, Pages 995-1011

  Donnan, Geoffrey A ^a   Howells, David W ^a,b   Markus, Romesh ^a   Toni, Danilo ^c   Davis, Stephen M ^d  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; 21 AMINOSTEROID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; ALTEPLASE; ANCROD; CITICOLINE; DESMOTEPLASE; DIZOCILPINE; ELIPRODIL; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; LACTACYSTIN BETA LACTONE; MONOCLONAL ANTIBODY; NADROPARIN; NEUTROPHIL INHIBITORY FACTOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASOME INHIBITOR; PROUROKINASE; STAPHYLOKINASE; TENECTEPLASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

BAT; BLEEDING; BLOOD CLOT LYSIS; BRAIN INFARCTION; BRAIN TISSUE; CLINICAL TRIAL; CONVALESCENCE; DESMODUS ROTUNDUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRIATE CORTEX; STROKE; TISSUE INJURY;

CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0344441853     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317140-00001     Document Type: Review

References (113)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349 (9063): 1436-42
2. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349 (9065): 1569-81
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 (24): 1581-7
4. Langhorne P, Williams BO, Gilchrist W, et al. Do stroke units save lives? Lancet 1993; 342 (8868): 395-8
5. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999; 354 (9188): 1457-63
6. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year: National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340 (23): 1781-7
7. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the ECASS Study Group. JAMA 1995; 274: 1017-25
8. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of tnrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352 (9136): 1245-51
9. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282 (21): 2019-26
10. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study. A randomized controlled trial: prolyse in acute cerebral thromboembolism. JAMA 1999; 282 (21): 2003-11
11. Wardlaw J, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke (Cochrane Review). The Cochrane Database of Systematic Reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 1999
12. Astrup J, Symon L, Siesjo BK. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 1981; 17: 723-5
13. Baron J, von Kummer R, del Zoppo G. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219-21
14. Marchal G, Beaudouin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke 1996; 27: 599-606
15. Heiss WD, Thiel A, Grond M, et al. Which targets are relevant for therapy of acute ischemic stroke? Stroke 1999; 30 (7): 1486-9
16. Heiss WD, Kracht LW, Thiel A, et al. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001; 124 Pt 1: 20-9
17. Read SJ, Hirano T, Abbott DF, et al. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 2000; 48 (2): 228-35
18. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54: 773-82
19. Memezawa H, Smith ML, Siesjo BK. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke 1992; 23 (4): 552-9
20. Heiss WD, Huber M, Fink GR, et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992; 12 (2): 193-203
21. Darby DG, Parsons MW, Barber PA, et al. Significance of acute multiple brain infarction on diffusion-weighted imaging. Stroke 2000; 31 (9): 2270-1
22. Read SJ. Positron emission tomography studies of acute stroke using 18F-fluoromisonidazole [dissertation]. Heidelberg: University of Melbourne, 1999
23. Jonas S, Aiyagari V, Vieira D, et al. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke: the predictive value of animal models. Ann N Y Acad Sci 2001; 939: 257-67
24. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276 (12): 961-6
25. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis: the Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31 (7): 1555-60
26. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55 (11): 1649-55
27. Andersen M, Overgaard K, Meden P, et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 1999; 30 (7): 1464-71
28. Carter LP, Guthkelch AN, Orozco J, et al. Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke 1992; 23 (6): 883-8
29. Del Zoppo GJ, Copeland BR, Waltz TA, et al. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke 1986; 17 (4): 638-43
30. Lekieffre D, Benavides J, Scatton B, et al. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 1997; 776 (1-2): 88-95
31. Overgaard K, Sereghy T, Pedersen H, et al. Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke. Neurol Res 1993; 15 (5): 344-9
32. Sakurama T, Kitamura R, Kaneko M. Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke. Stroke 1994; 25: 451-6
33. Sereghy T, Overgaard K, Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 1993; 24 (11): 1702-8
34. Zhang RL, Zhang ZG, Chopp M. Increased therapeutic efficacy with rt-PA and anti-CD 18 antibody treatment of stroke in the rat. Neurology 1999; 52 (2): 273-9
35. Rijken DC, Sakharov DV. Basic principles in thrombolysis: regulatory role of plasminogen. Thromb Res 2001; 103 Suppl. 1: S41-9
36. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91 (9): 3670-4
37. Nagai N, Vanlinthout I, Collen D. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 1999; 100 (25): 2541-6
38. Booth NA. Regulation of fibrinolytic activity by localization of inhibitors to fibrin (ogen). Fibrinolysis Proteolysis 2000; 14: 206-13
39. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270 (24): 14477-84
40. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384 (6605): 123-4
41. Pittman RN, Di Benedetto AJ. PC12 cells overexpressing tissue plasminogen activator regenerate neuntes to a greater extent and migrate faster than control cells in complex extracellular matrix. J Neurochem 1995; 64 (2): 566-75
42. Tsirka SE, Rogove AD, Bugge TH, et al. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17 (2): 543-52
43. Wang YF, Tsirka SE, Strickland S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4 (2): 228-31
44. Meng W, Wang X, Asahi M, et al. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1999; 19 (12): 1316-21
45. Klein GM, Li H, Sun P, et al. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology 1999; 52 (7): 1381-4
46. Wang X, Asahi M, Lo EH. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 1999; 274 (2): 79-82
47. Liberatore G, Samson A, Schleuning W, et al. Unlike tissue-type plasminogen activator, Desmodus rotundus (vampire bat) salivary plasminogen activator does not promote neurodegeneration. Stroke 2003; 34: 537-43
48. Parsons MW, Barber PA, Chalk J, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51 (1): 28-37
49. Schleuning WD. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001; 31 (3): 118-22
50. Diffusion-weighted imaging Evaluation For Understanding Stroke Evolution (DEFUSE) Study [online]. Available from URL: http://www.stanford.edu/group/ neurology/stroke/Introduction.htm [Accessed 2003 Sep 29]
51. Rother J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002; 33 (10): 2438-45
52. Stroke trials directory: ECASS-III [online]. Available from URL: http://www.strokecenter.org/trials/TrialDetail.asp?ref=475&browse=acute [Accessed 2003 Oct 28]
53. The Third International Stroke Trial (IST-3) [online]. Available from URL: http://www.dcn.ed.ac.uk/ist3/ [Accessed 2003 Sep 29]
54. Lijnen HR, Collen D. Staphylokinase. In: Backlin F, editor. Fibrinolytics and antifibrinolytics. Berlin: Springer-Verlag, 2001: 425-49
55. Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasmin (ogen), and fibrin: staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271 (44): 27912-8
56. Vanderschueren S, Van Vlaenderen I, Collen D. Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. Stroke 1997; 28 (9): 1783-8
57. Thomas GR, Thibodeaux H, Errett CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994; 25 (10): 2072-8
58. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95 (2): 351-6
59. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial: Thrombolysis in Myocardial Infarction (TIMI) 10B investigators. Circulation 1998; 98 (25): 2805-14
60. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial: the ASSENT-1 investigators. Am Heart J 1999; 137 (5): 786-91
61. Torr SR, Nachowiak DA, Fujii S, et al. 'Plasminogen steal' and clot lysis. J Am Coll Cardiol 1992; 19 (5): 1085-90
62. Chapman DF, Lyden P, Lapchak PA, et al. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001; 32 (3): 748-52
63. Zhang RL, Zhang L, Jiang Q, et al. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res 2000; 878 (1-2): 64-71
64. Kasai S, Arimura H, Nishida M, et al. Primary structure of single-chain pro-urokinase. J Biol Chem 1985; 260 (22): 12382-9
65. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67 (5): 1215-23
66. Tebbe U, Windeler J, Boesl I, et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study): liquemin in myocardial infarction during thrombolysis with saruplase. J Am Coll Cardiol 1995; 26 (2): 365-73
67. Gurewich V, Liu JN. Intra-arterial pro-urokinase in ischemic stroke. Stroke 1998; 29 (6): 1255-6
68. Reid H, Chan K, Thean P. Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963; I: 621-6
69. Bell WR, Pitney WR, Goodwin JF. Therapeutic defibrination in the treatment of thrombotic disease. Lancet 1968; I (7541): 490-3
70. Pollak VE, Glas-Greenwalt P, Olinger CP, et al. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990; 299 (5): 319-25
71. Prentice CR, Turpie AG, Hassanein AA, et al. Changes in platelet behaviour during arvin therapy. Lancet 1969; I (7596): 645-7
72. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study. A randomized controlled trial: Stroke Treatment with Ancrod Trial. JAMA 2000; 283: 2395-403
73. Sherman DG. Ancrod. Curr Med Res Opin 2002; 18 Suppl. 2: S48-52
74. Trouillas P, Nighoghossian N, Getenet J, et al. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke: correlations of outcome with clinical and radiological data. Stroke 1996; 27: 882-90
75. Trouillas P, Nighoghossian N, Derex L, et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke 1998; 29 (12): 2529-40
76. Freitag HJ, Becker VU, Thie A, et al. Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. Neuroradiology 1996; 38 (2): 181-5
77. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30 (12): 2598-605
78. Ernst R, Pancioli A, Tomsick T, et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000; 31 (11): 2552-7
79. Zaidat OO, Suarez JI, Santillan C, et al. Response to intraarterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002; 33 (7): 1821-7
80. Suarez JI, Zaidat OO, Sunshine JL, et al. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes. Neurosurgery 2002; 50 (2): 251-9
81. Hill MD, Barber PA, Demchuk AM, et al. Acute intravenous: intra-arterial revascularization therapy for severe ischemic stroke. Stroke 2002; 33 (1): 279-82
82. Keris V, Rudnicka S, Vorona V, et al. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. Am J Neuroradiol 2001; 22 (2): 352-8
83. The IMS Investigators. The Interventional Management of Stroke (IMS) Study: safety results [abstract]. Stroke 2003; 34 (1): 247
84. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22 (9): 391-7
85. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Pt II: mechanisms of damage and treatment. J Neurosurg 1992; 77 (3): 337-54
86. Globus MY, Busto R, Lin B, et al. Detection of free radical activity during transient global ischemia and recirculation: effects of intraischemic brain temperature modulation. J Neurochem 1995; 65 (3): 1250-6
87. Busch E, Kruger K, Allegrini PR, et al. Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging. J Cereb Blood Flow Metab 1998; 18 (4): 407-18
88. Yang Y, Li Q, Shuaib A. Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology 2000; 39 (5): 881-8
89. Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol 2000; 161 (2): 733-9
90. Bowes MP, Rothlein R, Fagan SC, et al. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995; 45(4): 815-9
91. Zhang RL, Zhang ZG, Chopp M, et al. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999; 30 (3): 624-9
92. Zhang L, Zhang ZG, Zhang RL, et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32 (12): 2926-31
93. Sanchez C, Alonso de Lecinana M, Diez-Tejedor E, et al. Treatment of embolic cerebral infarct via thrombolysis and cytoprotection with U-74389-G in rats [in Spanish]. Rev Neurol 1998; 27 (158): 653-8
94. Orozco J, Mendel RC, Hahn MR, et al. Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis. Neurol Res 1995; 17 (6): 423-5
95. Grotta J. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 2001; 12 (3): 258-63
96. Lyden P, Jacoby M, Schim J, et al. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology 2001; 57 (7): 1199-205
97. Hacke W, Lees K, Krams M, et al. An adaptive dose response finding study of UK-279,276 in acute ischemic stroke [abstract]. 28th International Stroke Conference; 2003 Feb 13-15; Phoenix. Stroke 2003; 34 (1): 248
98. Lindgren A, Lindoff C, Norrving B, et al. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996; 27 (6): 1066-71
99. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47 (10): 1075-9
100. Feinberg WM, Bruck DC, Jeter MA, et al. Fibrinolysis after acute ischemic stroke. Thromb Res 1991; 64 (1): 117-27
101. Weitz J, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106 (3): V275-84
102. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359 (9303): 294-302
103. Mikulski A, Elg M, Gustafsson D. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thromb Res 2001; 101 (6): 477-82
104. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272 (22): 14477-82
105. Minnema MC, Friederich PW, Levi, M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101 (1): 10-4
106. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94 (8): 2735-43
107. Refino CJ, DeGuzman K, Schmitt D, et al. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostatis. Fibrinolysis Proteolysis 2000; 14: 305-14
108. Nagashima M, Werner M, Wang M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98 (4): 333-42
109. Morita-Fujimura Y, Fujimura M, Gasche Y, et al. Over-expression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury-induced brain trauma. J Cereb Blood Flow Metab 2000; 20 (1): 130-8
110. Gasche Y, Copin JC, Sugawara T, et al. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001; 21 (12): 1393-400
111. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000; 107 (2): 140-7
112. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33 (3): 831-6
113. Lapchak PA, Araujo DM. Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 2001; 15 (11): 819-29